Amaravati Bonds and Andhra Pradesh's debt challenges
Dying to Survive: Indian generic medicines have a tale to tell
Geeks immune to the poll outcome, others seek systemic changes
Bengaluru's nerds did not vote. Should they complain?
Collective philanthropy model takes root in education
Realpolitik colours Andhra's debate over economic woes
Make in India in defence: Few JVs inked so far, but all lining up to take off
Why Indian pharma need to track Amazon's plans in health care
Need focus on health, not medical insurance
Medical Education Reform: Cure & Its Cost
Dialogue can sort out the National Medical Commission row
Fortis pricing controversy, a pointer to ignored issues in healthcare
Fresh salvo in the turf battle between innovator & generic drug makers
Indian pharma miffed with uncertainty, pricing issues
It is possible to nurse many govt hospitals back to good health. So, what is holding us back?
Questions that global generic behemoth Teva's results raise for Indian pharma
USFDA commissioner's comments raise new hopes for Indian pharma
Will the Lancet study be the wake-up call India needs on public health?
Need more than just generic drug prescriptions
Chandrababu Naidu's revenue challenge in Andhra
Post Jayalalithaa: Industry expects medium-term continuity but long-term concerns remain
Are you sure the medicine you are consuming is at the right price?
Celebrate good rains but watch out for monsoon-related infections
A Scientist's Take On Competing In A Free Market
Politics over Economics: Musings of a Pioneer
Who owns water and other questions
GSK shows a 'human face' but access of medicines to remain a challenge
Zika, the new buzzword
The passing away of a strategic developer
Did a red herring over drug safety put paid to India's first new drug?
Copyright © 2018 Living Media India Limited.